Ipilimumab
Acute Biphenotypic Leukemia
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
43 Active assets in the Acute Biphenotypic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2/3 | BB |
FILGRASTIM Ossium Health, Inc. | Phase 2 | BB |
Cytosin-Arabinosid University of Washington | Phase 2 | BB |
Busulphan Ossium Health, Inc. | Phase 2 | BB |
Cyclophosphamide Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Ipilimumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →